Overview

A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

We will conduct a trial to determine whether paclitaxel/cisplatin (TP) as an adjuvant chemotherapy after radical surgery improve disease-free survival (DFS) and overall survival (OS), as well as the quality of life (QoL) among early-stage (FIGO stage IB-IIA) cervical cancer patients with risk factors.

Phase:

N/A

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborators:

Shandong University
Zhejiang University

Treatments:

Cisplatin
Paclitaxel